Press release
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant ShareholderOramed will
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant ShareholderOramed will transfer POD™ platform to Lifeward while retaining management of clinical programOramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrantsMark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platformsIn addition, strategic investment by Oramed designed to bring Lifeward towards profitabilityLifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quartersNEW YORK, Jan. 13, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (\"Oramed\") and Lifeward Ltd. (NASDAQ: LFWD) (\"Lifeward\") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of Oramed's proprietary Protein Oral Drug POD™ delivery technology and Oramed obtaining 49.9% beneficial ownership interest in Lifeward upon the satisfaction of certain terms and conditions. In addition, Lifeward to issue $10 million in senior secured convertible notes in a private placement, of which Oramed to invest $9 million, and an additional milestone-based $10 million senior secured convertible note, of which Oramed will invest $9 million, each with 100% warrant coverage. The transaction allows Oramed to significantly increase its ownership stake in Lifeward upon full conversion of the notes and exercises of the warrants.\nStrategic VisionOramed believes this transaction represents a strategic evolution for Oramed, combining continued exposure to oral drug delivery innovation with participation in a medical robotics company which Oramed believes is positioned for significant growth. Upon consummation of the transaction, Lifeward will acquire Oramed's complete POD™ technology, representing years of research and development in transforming injectable therapies into oral medications. Under a clinical trial management agreement, Oramed is expected to manage the upcoming anticipated trial.Lifeward's leadership under President and CEO Mark Grant, who brings over 25 years of healthcare and medical technolog...